Accretive Wealth Partners LLC Has $360,000 Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Accretive Wealth Partners LLC decreased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 6.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,800 shares of the biotechnology company’s stock after selling 800 shares during the period. Accretive Wealth Partners LLC’s holdings in Exelixis were worth $360,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Los Angeles Capital Management LLC lifted its position in shares of Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Exelixis in the 3rd quarter valued at $14,979,000. Burney Co. bought a new stake in Exelixis in the fourth quarter valued at $12,267,000. Finally, Robeco Institutional Asset Management B.V. raised its stake in Exelixis by 263.1% during the third quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock worth $12,536,000 after acquiring an additional 350,026 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares in the company, valued at $9,828,514.55. This trade represents a 3.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,588 shares of company stock valued at $3,981,864. 2.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EXEL has been the topic of several analyst reports. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Exelixis in a research note on Wednesday, October 30th. Stephens restated an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday. Finally, Truist Financial upped their price target on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Price Performance

Exelixis stock opened at $35.00 on Friday. The firm has a market cap of $10.00 billion, a PE ratio of 22.44, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53. The stock’s fifty day moving average price is $34.19 and its two-hundred day moving average price is $30.83. Exelixis, Inc. has a one year low of $20.14 and a one year high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. Sell-side analysts expect that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.